Echocardiographic predictors of thrombus in left atrial appendage—The role of novel transthoracic parameters

Damian Kaufmann1, Elźbieta Wabich1, Agnieszka Kapton-Cieślicka2,3, Monika Gawałko2,3,4,5, Monika Budnik2,3, Beata Uziębło-Zyczkowska6, Paweł Krzesiński2,6, Katarzyna Starzyk7, Beata Wożakowska-Kapton7, Maciej Wójcik8, Robert Błaszczyk8, Jarosław Hiczkiewicz9,10, Jan Budzianowski9,10, Katarzyna Mizia-Stec2,11, Maciej T. Wybraniec2,11, Katarzyna Kosmalska12, Marcin Fijałkowski2,13, Anna Szymańska2,14, Mirostaw Dłužniewski14, Maciej Haberca2,15, Michał Kucio15, Błażej Michalski12,16, Karolina Kupczyńska2,16, Anna Tomaszuk-Kazberuk2,17, Katarzyna Wilk-Śledziewska2,17, Renata Wachnicka-Truty18, Marek Kozinski18, Paweł Burchardt19 and Ludmila Daniłowicz-Szymanowicz19

Introduction: The left atrium appendage thrombus (LAAT) formation is a complex process. A CHA₂DS₂-VASc scale is an established tool for determining the thromboembolic risk and initiation of anticoagulation treatment in patients with atrial fibrillation or flutter (AF/AFL). We aimed to identify whether any transthoracic echocardiography (TTE) parameters could have an additional impact on LAAT detection.
**Methods:** That is a sub-study of multicenter, prospective, observational study LATTEE (NCT03591627), which enrolled 3,109 consecutive patients with AF/AFL referred for transesophageal echocardiography (TEE) before cardioversion or ablation.

**Results:** LAAT was diagnosed in 8.0% of patients. The univariate logistic regression analysis [based on pre-specified in the receiver operating characteristic (ROC) analysis cut-off values with AUC $\geq 0.7$] identified left ventricular ejection fraction (LVEF) $\leq 48\%$ and novel TTE parameters i.e., the ratios of LVEF and left atrial diameter (LAD) $\leq 1.1$ (AUC 0.75; OR 5.64; 95% CI 4.03–7.9; $p < 0.001$), LVEF to left atrial area (LAA) $\leq 1.7$ (AUC 0.75; OR 5.64; 95% CI 4.02–7.9; $p < 0.001$), and LVEF to indexed left atrial volume (LAVI) $\leq 1.1$ (AUC 0.75; OR 6.77; 95% CI 4.25–10.8; $p < 0.001$) as significant predictors of LAAT. In a multivariate logistic regression analysis, LVEF/LAVI and LVEF/LAA maintained statistical significance. Calculating the accuracy of the abovementioned ratios according to the CHA$_2$DS$_2$-VASc scale values revealed their highest predictive power for LAAT in a setting with low thromboembolic risk.

**Conclusion:** Novel TTE indices could help identify patients with increased probability of the LAAT, with particular applicability for patients at low thromboembolic risk.

**KEYWORDS**
transthoracic echocardiography, left atrial appendage thrombus, NOAC, echocardiographic indices, thromboembolic risk, predictors of left atrial thrombus

**Introduction**

Atrial fibrillation and flutter (AF/AFL) are the most common sustained cardiac arrhythmias in adults (1, 2), with thromboembolic complications as the main reason for morbidity and mortality (3). The CHA$_2$DS$_2$-VASc scale is an established clinical tool which is recommended for determining the thromboembolic risk and anticoagulation treatment indications in AF/AFL patients (4). However, thrombus formation is a complex process, which involves many hemorheological, tissue and humoral factors; hence the mere assessment of the thrombus mass formation based only on the abovementioned scale could be insufficient (5). Therefore, it could be reasonable to relate the CHA$_2$DS$_2$-VASc scale to some morphological parameters, which could have a possible impact on thrombus development, and echocardiography could be a valuable tool in this issue. Transesophageal echocardiography (TEE) is regarded as the gold standard in detecting the left atrial (LA) appendage thrombus (LAAT) before cardioversion or ablation procedure (6, 7). However, in certain situations, its performance is hampered or even not possible, for instance, due to logistical difficulties related to restricting access to the TEE in small district hospitals, as well as in certain situations, such as the COVID-19 pandemic, in which the implementation of the study was limited. Therefore, it seems reasonable to verify whether any routinely assessed transthoracic echocardiography (TTE) parameters could help identify patients with a high probability of LAAT, which could allow clinicians to avoid unnecessary diagnostics and influence the appropriate management of a patient.

Many studies have focused so far on the search for echocardiographic parameters that predict the risk of LAAT (8–11), revealing LA enlargement [both diameter (LAD), surface area (LAA), indexed volume (LAVI)], and decreased left ventricular ejection fraction (LVEF) as the most associated with thrombus formation. However, the predictive power of these conventional variables is insufficient (8, 9). Therefore, we hypothesized that perhaps parameters determining the size, area, and volume of the atrium, in combination with other echocardiographic parameters such as LVEF, may prove valuable as a marker of increased risk of LAAT formation in real-world AF/AFL patients referred for TEE before electrical cardioversion or catheter ablation in the era of modern anticoagulation.

**Materials and methods**

**Study population**

The study is a sub-analysis of the real-world Left Atrial Thrombus on Transesophageal Echocardiography (LATTEE)
registry (NCT03591627), which evaluated the determinants of LAAT depending on echocardiographic and clinical parameters in patients with AF/AFL referred for electrical cardioversion or catheter ablation. Exact details on the study rationale and design have been published previously (12), while the primary data concerning the prevalence of a thrombus depending on anticoagulation strategy were further precisely delineated (13). In sum, the LATTEE was a prospective, observational study enrolling consecutive patients with AF/AFL admitted to 13 cardiology departments between November 2018 and May 2020 in whom TEE was performed before direct current cardioversion or catheter ablation. Diagnosis of AF/AFL was based on previous European Society of Cardiology Guidelines on managing AF by attending physicians (14). Regarding non-emergency electrical cardioversion for AF/AFL, four centers performed TEE routinely in all patients, and nine centers performed TEE only in those patients who were suspected of ineffective antithrombotic therapy within the last 3 weeks. The study was conducted according to clinical practice guidelines and the Declaration of Helsinki. The Ethics Committee approved the study of the Medical University of Warsaw (AKBE/113/2018), which waived the requirement of obtaining informed consent from the patients.

### TABLE 1 Comparison of the clinical characteristics between patients with (LAAT+) and without LAAT (LAAT).

| Variable | LAAT- (n = 2,859) | LAAT+ (n = 250) | p<sup>a</sup> |
|----------|------------------|----------------|---------|
| **Demographics** | | | |
| Age (years) | 67 [59–73] | 72 [64–78] | <0.001 |
| AF/AFL type | | | |
| AF/AFL paroxysmal | 1,247 (44%) | 33 (13%) | <0.001 |
| AF/AFL persistent | 1,365 (48%) | 183 (73%) | <0.001 |
| AF/AFL long-standing persistent | 237 (8%) | 34 (14%) | 0.007 |
| AF chronic | 109 (4%) | 20 (8%) | 0.004 |
| **Comorbidities** | | | |
| Heart failure | 1,165 (41%) | 171 (69%) | <0.001 |
| Heart failure with reduced LVEF | 380 (13%) | 96 (39%) | <0.001 |
| Hypertension | 2,171 (76%) | 195 (79%) | <0.393 |
| Diabetes mellitus | 683 (24%) | 91 (37%) | <0.001 |
| Previous stroke | 206 (7.2%) | 29 (12%) | 0.017 |
| TIA | 75 (3%) | 15 (6%) | 0.005 |
| Previous ischemic stroke/TIA/systemic embolism | 278 (9.7%) | 35 (14%) | 0.040 |
| Previous hemorrhagic stroke | 14 (0.5%) | 3 (1.2%) | 0.148 |
| Vascular disease | 949 (33%) | 118 (47%) | <0.001 |
| Myocardial infarction | 372 (13%) | 59 (28%) | <0.001 |
| Coronary artery disease | 811 (29%) | 94 (38%) | 0.002 |
| Peripheral artery disease | 149 (5%) | 26 (10%) | <0.001 |
| Moderate to severe mitral stenosis | 12 (0.4%) | 5 (2%) | 0.009 |
| Moderate to severe mitral regurgitation | 442 (15%) | 81 (32%) | <0.001 |
| Moderate to severe aortic stenosis | 47 (1.6%) | 15 (6%) | <0.001 |
| CIED | 341 (12%) | 57 (23%) | <0.001 |
| eGFR < 50 (mL/min) | 82 [64–103] | 74 [51–93] | <0.001 |
| Previous bleeding | 114 (4.0%) | 17 (6.9%) | 0.05 |
| Anemia | 431 (16%) | 53 (23%) | <0.01 |
| Labile INR | 56 (2%) | 23 (9%) | <0.001 |
| Smoking | 902 (33%) | 109 (46%) | <0.001 |
| Alcohol | 106 (4%) | 23 (9%) | <0.001 |
| **Thromboembolic risk and indications to chronic OAC** | | | |
| CHA<sub>2</sub>DS<sub>2</sub>-VASc score | 3 [2–4] | 4 [3–5] | 0.010 |
| **Antithrombotic therapy** | | | |
| Chronic OAC therapy | 2,553 (89%) | 200 (80%) | <0.001 |

<sup>a</sup>p-value refers for the differences between LAAT (+) and LAAT (-) groups.

AF, atrial fibrillation; AFL, atrial fibrillation; CIED, cardiac implanted electrical device; eGFR, estimated glomerular filtration rate; INR, international normalized ratio; LAAT, left atrial appendage thrombus; MS, mitral stenosis; OAC, an oral anticoagulant. TIA, transient ischemic attack.
Data collection and study endpoint

Data were gathered prospectively and included precise demographics, medical history, comorbidities, CHA\textsubscript{2}-DS\textsubscript{2}-VASC score calculation, pharmacotherapy, and results of routine laboratory blood tests. Chronic oral anticoagulation (OAC) was defined as OAC treatment for at least 3 weeks before the procedure. In all patient’s obligatory transoesophageal echocardiography (TOE) parameters such as presence and location of LAAT, presence of spontaneous echocardiographic contrast, as well as LAA outflow velocity (LAAV) were obtained. TTE study was conducted in the vast majority of participants and involved gathering data regarding: LVEF, LAD, LAA, left atrial volume (LAV) and LAVI (calculated as a ratio of left atrial volume to body surface area). Trained echocardiographers performed all examinations as it was defined in the primary protocol (12). Additionally, the novel parameters (ratios of LVEF and LA parameters: LVEF/LAD, LVEF/LAA, and LVEF/LAVI) were investigated. Both TTE and TOE parameters were analyzed and interpreted locally. The primary endpoint of the study was the presence of LAAT.

Statistical analysis

Continuous data were presented as the median (25th–75th percentiles), categorical as a number (n) and percentage (%). Differences between LAAT+ and LAAT- groups were calculated with the Mann-Whitney U-test and the qualitative data with the \(\chi^2\) or Yates \(\chi^2\) test. The accuracy of pre-specified cut-off values for analyzed parameters and their association as potential predictors of the study endpoint was determined by area (AUC) under the receiver operating characteristic (ROC) curve. Only AUC values \(\geq 0.7\) were considered for further analysis (15). For comparison of unpaired ROC curves, the Venkatraman’s test was utilized. The association between the analyzed parameters (differed between LAAT+ and LAAT- groups) and the endpoint was assessed using univariable logistic regression analysis with cut-off values pre-specified in ROC analysis. Multivariable analysis was applied to continuous data (dichotomized according to the cut-off values identified in ROC analyses) and categorical data associated with the endpoint in the univariable regression analysis (\(p \leq 0.05\)). The set of variables accepted for the model was determined by the backward elimination method from the set of all statistically significant predictors. The statistical analysis was conducted with an R 4.0.5 environment (R Core Team, Vienna, Austria).

Results

Study population

A total of 3,109 patients who met the inclusion criteria were enrolled in the LATTEE registry. Altogether, nearly 9 out of 10 were on OACs. Prevalence of LAAT was 8.0% (7.3% on chronic OAC vs. 15% without OAC; \(p < 0.001\)) and it was doubled in patients on vitamin K antagonist (VKA) compared to patients on non-VKA-OACs (NOACs) (13 vs. 6.0%; \(p < 0.01\)). Patients with LAAT were older and more often had chronic AF and comorbidities, resulting in a higher CHA\textsubscript{2}-DS\textsubscript{2}-VASC score, as shown in Table 1. All clinical parameters of the study population were presented in previous work (13).

Echocardiographic parameters

TTE data were obtained for 2,599 (84%) study participants, and Table 2 presents the results. LAAT+ patients had lower LVEF and greater LAD, LAA, LAV, and LAVI values. The compared groups differed significantly in terms of the echocardiographic indices, i.e., LAAT+ in comparison to LAAT- patients had a lower ratio of LVEF to LA indices: LVEF/LAD \(0.9 \text{ vs. } 1.2 (p < 0.001)\), LVEF/LAA 1.4 vs. 2.1 \(p < 0.001\), and LVEF/LAVI 0.7 vs. 1.2 respectively \(p < 0.001\), as shown in Table 2.

Significant predictors of left atrial thrombus

Table 3 presents the results of ROC analysis with pre-specified cut-off values for LAAT prediction. The LA parameters alone did not have adequate predictive power (AUC lower than \(0.7\)), whereas ratios of LVEF with LA parameters significantly improved the level of LAAT prediction with high specificity and positive predictive value.

The univariate logistic regression analysis (based on pre-specified in the ROC analysis cut-off values with AUC \(\geq 0.7\)) revealed a considerable number of clinical parameters, as well

---

### Table 2: Comparison of LVEF, LA parameters and ratios in LAAT+ and LAAT- patients.

| Variable          | LAAT- (n = 2,859) | LAAT+ (n = 250) | \(p^a\) |
|-------------------|------------------|----------------|--------|
| LVEF (%)          | 55 [45–60]       | 40 [30–51]     | <0.001 |
| LAD (mm)          | 45 [41–49]       | 47 [45–51]     | <0.001 |
| LAA (cm\(^2\))    | 26 [22–30]       | 28 [24.8–35]   | <0.001 |
| LAV (ml)          | 85 [69–109]      | 97 [76–123]    | <0.001 |
| LAVI (ml/m\(^2\))| 44 [35–55]       | 52 [42.9–63]   | <0.001 |
| LVEF/LAD ratio    | 1.2 [0.98–1.4]   | 0.9 [0.62–1.09]| <0.001 |
| LVEF/LAA ratio    | 2.1 [1.6–2.51]   | 1.4 [0.97–1.83]| <0.001 |
| LVEF/LAVI ratio   | 1.2 [0.88–1.57]  | 0.7 [0.52–1.05]| <0.001 |

\(p^a\) values refer for the differences between LAAT+ and LAAT- groups.

LAA, left atrial area; LAD, left atrial diameter; LAAT, left atrial appendage thrombus; LAV, left atrial volume; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction.
as LVEF, LVEF/LAD, LVEF/LAA and LVEF/LAVI ratios as the significant predictors for LAAT. These data are presented in Figure 1. C-Statistics analyses showed that the accuracy power of new echocardiographic indices (LVEF/LAD, LVEF/LAA, LVEF/LAVI) differed significantly from conventional parameters (LAD, LAA, LAVI—in all combinations p < 0.05) but not for LVEF (p > 0.05). In a multivariate logistic regression analysis, which included all parameters which proved to be statistically significant in the univariate test (with AUC ≥ 0.7 for continuous variables from Table 3), only a few clinical parameters, as well as LVEF/LAVI and LVEF/LAA ratio maintained its statistical significance, as shown in Figure 1.

Significant predictors of left atrial appendage thrombus in subpopulation of patients with heart failure

Among the entire study population, 43% of the patients, i.e., 1,336, were diagnosed with heart failure (HF). Of the HF types, the most common was HF with preserved ejection fraction (HfPEF), then reduced ejection fraction (HfREF) and mid-range ejection fraction (HfMfEF), 38, 35, and 27%, respectively. Most HF patients had symptoms consistent with NYHA I-II (72%).

The results of logistic regression analysis and ROC with specific cut-off values for LAAT prediction in patients with HF subtypes are presented in Table 4. In each of the HF subtypes tested, AUC and OR values were lower than those obtained for the entire study population. The new echocardiographic indices differed in statistical power depending on the HF subtype, and more precisely, they had highest prediction for LAAT formation in patients with HfPEF, where they obtained acceptable values for LVEF/LAA ≤ 1.8 [AUC 0.7, OR 4.1, 95% CI (1.9–9), p = 0.001] and LVEF/LAVI ≤ 1.1 [0.71, OR 4.4, 95% CI (1.7–11.6), p = 0.003].

TABLE 3 Accuracy of the pre-specified cut-off values for analyzed parameters as the predictors of LAAT.

| Parameter | AUC | Characteristics (%) | Predictive value (%) |
|-----------|-----|---------------------|----------------------|
|           |     | Sensitivity | Specificity | Positive | Negative |
| Age ≥ 72 years | 0.61 | 74 | 46 | 94 | 13 |
| LVEF ≤ 48% | 0.74 | 71 | 65 | 96 | 17 |
| LAD ≥ 45 mm | 0.63 | 53 | 67 | 95 | 12 |
| LAA ≥ 26 cm² | 0.62 | 53 | 66 | 94 | 12 |
| LAV ≥ 89 mL | 0.59 | 55 | 59 | 93 | 11 |
| LAVI ≥ 51 mL/m² | 0.64 | 68 | 54 | 94 | 14 |
| LVEF/LAD ratio ≤ 1.1 | 0.75 | 62 | 79 | 97 | 16 |
| LVEF/LAA ratio ≤ 1.7 | 0.75 | 71 | 70 | 96 | 18 |
| LVEF/LAVI ratio ≤ 1.1 | 0.75 | 56 | 84 | 97 | 15 |

AUC, an area under the curve; CI, confidence interval; LAA, left atrial area; LAD, left atrial diameter; LAAT, left atrial appendage thrombus; LAV, left atrial volume; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction.

Accuracy of transthoracic echocardiographic indices for left atrium appendage thrombus detection according to CHA2DS2-VASc score values

Based on the statistical significance of novel echocardiographic ratios, we determined their odds ratio for LAAT prediction in different CHA2DS2-VASc groups. For this purpose, we divided patients into three subgroups accordingly to (A) 0–1, (B) 2–3, and (C) 4 and more points on the CHA2DS2-VASc score. In ROC analysis, the appropriate cut-off values for LAAT prediction were determined, as shown in Table 5. The obtained data show that the discussed indices were characterized by better accuracy and predictive power than conventional parameters, and that the LVEF/LAA index predicts the formation of LAAT with the highest statistical power.

Discussion

The major finding in this prospective, observational study is that LAAT formation was strongly associated with echocardiographic parameters, additionally to well-known clinical variables. We determined that simple, routinely examined echocardiographic parameters presented as the novel indices, including LVEF and LA parameters seem to be accurate predictors of LAAT presence, mainly according to different CHA2DS2-VASc score groups with peculiar applicability for patients with relatively lower thromboembolic risk.

To date, several risk stratification methods utilizing clinical parameters have been developed to help pinpoint patients with AF/AFL who are at high risk for thromboembolic
complications, among which the most recognized is the CHA2DS2-VASc score (16). Nonetheless, some other investigators had a differing viewpoint on this issue (17, 18). The role of data derived from the TTE study as a marker of LAAT formation has been studied extensively over the last decades (10, 19–22). For example, in the study of Scherr et al., which enrolled 585 patients referred for catheter ablation of AF, LAD ≥ 45 mm and a CHADS2 score ≥ 2 proved to be significant predictors of LA thrombus in multivariate regression analysis (10). Our data are in line with those observations. Moreover, the capacity for predicting LAAT by combining LA area and volume parameters and LVEF seems stronger than using any single echocardiographic parameter. In our study, we proposed some novel echocardiographic indices, easy to obtain from the routinely checked parameters, which could have an additional impact on LAAT detection.
Of the TTE indices, the LVEF/LAD with a cut-off value of ≤ 1.1, LVEF/LAA ratio ≤ 1.7 and LVEF/LAVI ≤ 1.1 had the highest predictive accuracy (AUC ≥ 0.7) predictive power and statistical significance in the univariate logistic regression analysis. Importantly, in the multivariate logistic regression analysis, LVEF/LAVI and LVEF/LAA maintained statistical significance.

For better prediction of LAAT, models combining clinical and echocardiographic parameters have been proposed (17, 19–24). For example, Van Chien et al., in their study of 144 anticoagulant-naive patients, proposed models that combined CHA\textsubscript{2}-DS\textsubscript{2}-VASc score with LA volume index and LA longitudinal strain (17). In another study conducted by Ayirala et al. on 334 patients who received VKA or VKA and heparin, the authors showed that patients with CHADS\textsubscript{2} score of ≤ 1 a normal LAVI in combination with normal LVEF are a robust negative predictor of LAA thrombus formation (19). Our results are under data from the literature; indeed, the calculation of LVEF/LAVI and LVEF/LAA ratio in different CHA\textsubscript{2}-DS\textsubscript{2}-VASc score groups had a significant association with LAAT. Notably, the highest OR for LAAT prediction of presented echocardiographic indexes is for patients with low thromboembolic risk (Table 5). For example, LVEF/LAA index ≤ 1.5 in low-risk patients (with 0 or 1 points in CHA\textsubscript{2}-DS\textsubscript{2}-VASc score) was characterized by an OR 3.9, CI 1.4–10.4 with an excellent AUC equal to 0.92. Similarly, the positive predictive value of the pre-specified cut-offs was higher for patients with a lower CHA\textsubscript{2}-DS\textsubscript{2}-VASc score. That could be of great clinical value, helping clinicians identify patients with a high likelihood of LAAT, regardless of a low CHA\textsubscript{2}-DS\textsubscript{2}-VASc score.

HF patients constitute a special population within atrial fibrillation patients, and their increasing coexistence is associated with significantly elevated in-hospital mortality (25). The occurrence of AF in patients with HF may lead to clinical

### Table 4
Univariate regression analysis and ROC study results of novel echocardiographic parameters in subpopulation of patients with HF.

| Parameter | AUC | OR 95% | p\textsuperscript{a} |
|-----------|-----|--------|----------------|
| HF with reduced EF | | | |
| LVEF/LAA ≤ 1.0 | 0.59 | 2 [1.2–3.4] | 0.01 |
| LVEF/LAVI ≤ 0.6 | 0.56 | 2.1 [1.1–4.1] | 0.023 |
| HF with mid-range EF | | | |
| LVEF/LAA ≤ 1.5 | 0.68 | 2.2 [1.1–4.6] | 0.033 |
| LVEF/LAVI ≤ 0.9 | 0.60 | 3.8 [3.6–9.2] | 0.002 |
| HF with preserved EF | | | |
| LVEF/LAA ≤ 1.8 | 0.70 | 4.1 [1.9–9] | 0.001 |
| LVEF/LAVI ≤ 1.1 | 0.71 | 4.4 [1.7–11.6] | 0.003 |
| HF with mid-range EF and HF with reduced EF | | | |
| LVEF/LAA ≤ 2 | 0.67 | 4.3 [2.1–8.9] | 0.001 |
| LVEF/LAVI ≤ 1 | 0.72 | 4.5 [2.3–8.5] | 0.001 |

\textsuperscript{a}p\textsuperscript{-values refer for the differences between LAAT (+) and LAAT (-) groups.}

AUC, an area under the curve; EF, ejection fraction; HF, heart failure; LAA, left atrial area; LAD, left atrial diameter; LAAT, left atrial thrombus; LVEF, left ventricular ejection fraction; OR, odds ratio.

### Table 5
Accuracy of echocardiographic indices in LAAT prediction according to CHA\textsubscript{2}-DS\textsubscript{2}-VASc score values.

| Parameters | AUC | Characteristics (%) | Predictive value (%) | OR 95% | p\textsuperscript{a} |
|------------|-----|---------------------|---------------------|--------|----------------|
|            |     | Sensitivity | Specificity | Positive | Negative |   |
| Subgroup A (CHA\textsubscript{2}-DS\textsubscript{2}-VASc 0–1 point) | | | | | | |
| LVEF/LAA ≤ 1.5 | 0.92 | 89 | 89 | 100 | 17 | 29 [5.9–145] | <0.001 |
| LVEF/LAVI ≤ 0.7 | 0.78 | 92 | 60 | 98 | 21 | 18 [4.7–68] | <0.001 |
| LVEF ≤ 48% | 0.72 | 85 | 62 | 99 | 9 | 9 [2.8–25] | <0.001 |
| LAD ≥ 41 mm | 0.74 | 37 | 100 | 100 | 4 | 15 [0.9–264] | 0.003 |
| LAA ≥ 26 cm\textsuperscript{2} | 0.79 | 62 | 100 | 100 | 6 | 29 [1.7–511] | <0.001 |
| Subgroup B (CHA\textsubscript{2}-DS\textsubscript{2}-VASc 2–3 points) | | | | | | |
| LVEF/LAA ≤ 1.5 | 0.77 | 78 | 72 | 97 | 22 | 9 [5–16.2] | <0.001 |
| LVEF/LAVI ≤ 0.9 | 0.75 | 77 | 67 | 96 | 21 | 6.6 [3.5–12.2] | <0.001 |
| LVEF ≤ 47% | 0.76 | 74 | 68 | 96 | 19 | 5.9 [3.7–10] | <0.001 |
| LAD ≥ 45 mm | 0.67 | 53 | 74 | 96 | 12 | 3.2 [1.8–5.2] | <0.001 |
| LAA ≥ 29 cm\textsuperscript{2} | 0.67 | 69 | 58 | 95 | 14 | 3.1 [1.8–5.1] | <0.001 |
| Subgroup C (CHA\textsubscript{2}-DS\textsubscript{2}-VASc 4 and more points) | | | | | | |
| LVEF/LAA ≤ 2.0 | 0.70 | 43 | 87 | 96 | 17 | 4.3 [2.5–7.4] | <0.001 |
| LVEF/LAVI ≤ 0.9 | 0.69 | 70 | 64 | 94 | 20 | 3.7 [2.3–6.1] | <0.001 |
| LVEF ≤ 55% | 0.70 | 38 | 92 | 98 | 15 | 7.7 [3.7–14.3] | 0.001 |
| LAD ≥ 44 mm | 0.55 | 39 | 72 | 92 | 13 | 1.7 [1.1–2.5] | 0.019 |
| LAA ≥ 29 cm\textsuperscript{2} | 0.55 | 29 | 82 | 92 | 13 | 1.8 [1.1–3.1] | 0.02 |

\textsuperscript{a}p\textsuperscript{-values refer for the differences between LAAT (+) and LAAT (-) groups.}

AUC, an area under the curve; EF, ejection fraction; HF, heart failure; LAA, left atrial area; LAD, left atrial diameter; LAAT, left atrial thrombus; LVEF, left ventricular ejection fraction; OR, odds ratio.
disease progression and increases mortality, on the other hand, presence of HF in AF patients interfere with preservation of sinus rhythm through atrial remodeling, increases the number of strokes and mortality (26, 27). Despite the fact that congestive HF is a part of CHA\textsubscript{2}-DS\textsubscript{2}-VASc score whether every HF subtype generates the same risk of LAAT formation is still in question (28, 29). In a recently published work, also based on data from the LATTEE registry Wybraniec et al. examined a population of 1,336 patients with HF and showed that the diagnosis of HFrEF, but neither HFmrEF nor HFpEF, confers a considerable risk of LAT formation (30). In our study we evaluated the usefulness of the new echocardiographic parameters i.e., LVEF/LAA and LVEF/LAVI in all HF subtypes, however, the results are unsatisfactory and indicate the need to look for other LAT predictors in this group of patients.

Based on our results, it could be suggested that clinical risk scores should be combined with echocardiographic parameters to receive the most accurate data regarding LAAT formation. A significant advantage of our results boosts the fact that our research was based on a large, modernly anticoagulated group of patients, 82% of whom were on chronic NOAC. To the best of our knowledge, this is the first study that shows the usefulness of novel echocardiographic parameters in clinical presentation in identifying high-risk individuals of LAAT occurrence in the era of contemporary anticoagulation.

**Limitations of the study**

Our study has some limitations. Firstly, the study was a registry and therefore has a limitation of its design. Secondly, despite the fact that we included a relatively large group of patients with AF/AFL, by inclusion criteria these were patients admitted for ablation or cardioversion procedures and therefore, the results cannot be extrapolated to the whole population of patients with AF/AFL. Thirdly, it is worth noting that echocardiographic study was performed at the discretion of attending physicians, and thus, data including TTE are missing for some patients. Moreover, a few promising parameters, such as LV stroke volume, LV end-systolic and end-diastolic volume as well as parameters of left ventricular diastolic dysfunction and peak atrial longitudinal strain that could identify patients at increased risk of LAAT, were not included in the methodology of that registry (31, 32). Additionally, the study did not investigate into the rate of ischemic stroke on follow-up, but only the presence of LAAT. Furthermore, TOE was performed routinely in most centers prior to direct current cardioversion and catheter ablation, however, some participating centers performed TOE only in subjects with suboptimal anticoagulation before the procedure or in those with doubts regarding adherence to NOAC and its effectiveness which might have led to some selection bias. Finally, study aimed to check which echocardiographic parameters can predict LAAT formation based on regular patients qualified to TEE in the everyday clinical practice hence we did not exclude a peculiar group of patients with “valvular AF” from the analysis.

**Conclusion**

Simple, routinely examined echocardiographic parameters presented as the novel indices, including LVEF and LA parameters, seem to be accurate predictors of LAAT presence. Further use of those parameters could help predict LAAT in different CHA\textsubscript{2}-DS\textsubscript{2}-VASc score groups with particular applicability for patients with low thromboembolic risk.

**Data availability statement**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**Ethics statement**

The studies involving human participants were reviewed and approved by the Ethics Committee of the Medical University of Warsaw. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

**Author contributions**

DK and LD-S: formal analysis, resources, writing—original draft preparation, visualization, data curation, and agreed to the published version of the manuscript. AK-C, MG, and MB: conceptualization, methodology, validation, investigation, data curation, writing—review and editing, project administration, and agreed to the published version of the manuscript. EW, BU-Ż, PK, KS, MCW, RB, JH, JB, KM-S, MTW, KTK, MF, AS, MD, MH, MCK, BM, KRK, AT-K, KW-Ś, RW-T, MRK, and PB: investigation, data curation, writing—review and editing, and agreed to the published version of the manuscript. LD-S: conceptualization, methodology, resources, writing—original draft preparation, visualization, supervision, data curation, and agreed to the published version of the manuscript. All authors contributed to the article and approved the submitted version.

**Acknowledgments**

The LATTEE Registry was initiated on the Scientific Platform of the “Club 30” of the Polish Cardiac Society. We thank IG-G for helping with data collection.
Conflict of interest

Authors AK-C, BW-K, and MRK received honoraria for lectures from Bayer, Boehringer Ingelheim, and Pfizer, outside the submitted work. Author LD-S received speaker fees from Bayer, Boehringer Ingelheim, and Pfizer—outside the submitted work. Author KM-S received speaker fees from Bayer, Pfizer, Boehringer Ingelheim, AstraZeneca, Novartis, and Servier—outside the submitted work. Author AT-K received speaker fees from Boehringer-Ingelheim—outside the submitted work.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
25. Reinhardt SW, Chouairi F, Miller PJ, Clark KAA, Kay B, Fuery M, et al. National trends in the burden of atrial fibrillation during hospital admissions for Heart failure. *J Am Heart Assoc.* (2021) 10:e019412. doi: 10.1161/JAHA.120.019412

26. Liao Y-C, Liao J-N, Lin Y-J, Chang S-L, Hu Y-P, et al. Left atrial size and left ventricular end-systolic dimension predict the progression of paroxysmal atrial fibrillation after catheter ablation: predictors of AF progression after ablation. *J Cardiovasc Electrophysiol.* (2017) 28:23–30. doi: 10.1111/jce.13115

27. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham heart study. *Circulation.* (2003) 107:2928–5. doi: 10.1161/01.cir.0000072767.89944.6e

28. Sartipy U, Dahlström U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. *JACC Heart Fail.* (2017) 5:565–74. doi: 10.1016/j.jchf.2017.05.001

29. Mulder BA, van Veldhuisen DJ, Rienstra M. What should the C ('congestive heart failure') represent in the CHA 2 DS 2 -VASc score? *Eur J Heart Fail.* (2020) 22:1294–7. doi: 10.1002/ejhf.1946

30. Wybraniec MT, Mizia-Szubryt M, Cichori M, Wrona-Kolasa K, Kaplon-Cieslicka A, Gawalko M, et al. Heart failure and the risk of left atrial thrombus formation in patients with atrial fibrillation or atrial flutter. *ESC Heart Fail.* (2022). [Epub ahead of print]. doi: 10.1002/ejhf.14105

31. Cameli M, Lunghetti S, Mandoli GE, Righini FM, Lisi M, Curci V, et al. Left atrial strain predicts pro-thrombotic state in patients with non-valvular atrial fibrillation. *J Atr Fibrillation.* (2017) 10:1641. doi: 10.4022/jafib.1641

32. Doukkly R, Garcia-Sayan E, Gage H, Nagarajan V, Demopoulos A, Cena M, et al. The value of diastolic function parameters in the prediction of left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. *Cardiovasc Ultrasound.* (2014) 12:10. doi: 10.1186/1476-7120-12-10

COPYRIGHT © 2022 Kaufmann, Wabich, Kaplon-Cieslicka, Gawalko, Budnik, Uziębło-Zyczkowska, Krzesiński, Starzyk, Wozakowska-Kapton, Wójcik, Błaszczyk, Hiszczkiewicz, Budzionowski, Mizia-Stec, Wybraniec, Kosmalska, Fijałkowski, Szymanis, Dłużniewski, Haberka, Kucio, Michalski, Kupczyńska, Tomaszuk-Kazberuk, Wilk-Stężyńska, Wachnicka-Truty, Koziński, Burchardt and Daniłowicz-Szymanowicz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.